Wang Nisha, Ma Jipeng, Ma Yan, Lu Linhe, Ma Chao, Qin Pei, Gao Erhe, Zuo Mingzhang, Yang Jian, Yang Lifang
Department of Anesthesiology, Xi'an Children's Hospital, Xi'an Jiaotong University, Xi'an, China.
Department of Cardiovascular Surgery, Xijing Hospital, Air Force Medical University, Xi'an, China.
Front Cardiovasc Med. 2021 Jun 14;8:629547. doi: 10.3389/fcvm.2021.629547. eCollection 2021.
Myocardial ischemia/reperfusion injury is a common clinical problem and can result in severe cardiac dysfunction. Previous studies have demonstrated the protection of electroacupuncture against myocardial ischemia/reperfusion injury. However, the role of X-box binding protein I (XBP1) signaling pathway in the protection of electroacupuncture was still elusive. Thus, we designed this study and demonstrated that electroacupuncture significantly improved cardiac function during myocardial ischemia/reperfusion injury and reduced cardiac infarct size. Electroacupuncture treatment further inhibited cardiac injury manifested by the decrease of the activities of serum lactate dehydrogenase and creatine kinase-MB. The results also revealed that electroacupuncture elevated the expressions of XBP1, glucose-regulated protein 78 (GRP78), Akt, and Bcl-2 and decreased the Bax and cleaved Caspase 3 expressions. By using the inhibitor of XBP1 , the results revealed that suppression of XBP1 expression could markedly increase the activities of lactate dehydrogenase and creatine kinase-MB and cell apoptosis, thus exacerbating stimulated ischemia/reperfusion-induced H9c2 cell injury. Compared with stimulated ischemia/reperfusion group, inhibition of XBP1 inhibited the downstream GRP78 and Akt expressions during stimulated ischemia/reperfusion injury. Collectively, our data demonstrated that electroacupuncture treatment activated XBP1/GRP78/Akt signaling to protect hearts from myocardial ischemia/reperfusion injury. These findings revealed the underlying mechanisms of electroacupuncture protection against myocardial ischemia/reperfusion injury and may provide novel therapeutic targets for the clinical treatment of myocardial ischemia/reperfusion injury.
心肌缺血/再灌注损伤是一个常见的临床问题,可导致严重的心功能障碍。先前的研究已证实电针对心肌缺血/再灌注损伤具有保护作用。然而,X盒结合蛋白1(XBP1)信号通路在电针保护作用中的作用仍不清楚。因此,我们设计了本研究,并证明电针可显著改善心肌缺血/再灌注损伤期间的心功能,并减小心肌梗死面积。电针治疗进一步抑制了以血清乳酸脱氢酶和肌酸激酶-MB活性降低为表现的心脏损伤。结果还显示,电针可提高XBP1、葡萄糖调节蛋白78(GRP78)、Akt和Bcl-2的表达,并降低Bax和裂解的半胱天冬酶3的表达。通过使用XBP1抑制剂,结果显示抑制XBP1表达可显著增加乳酸脱氢酶和肌酸激酶-MB的活性以及细胞凋亡,从而加剧模拟缺血/再灌注诱导的H9c2细胞损伤。与模拟缺血/再灌注组相比,抑制XBP1可抑制模拟缺血/再灌注损伤期间下游GRP78和Akt的表达。总的来说,我们的数据表明电针治疗激活XBP1/GRP78/Akt信号通路以保护心脏免受心肌缺血/再灌注损伤。这些发现揭示了电针保护心肌缺血/再灌注损伤的潜在机制,并可能为心肌缺血/再灌注损伤的临床治疗提供新的治疗靶点。